Friedreich Ataxia Scientific News
Friedreich Ataxia and close related scientific news. Topics related to rare diseases.
Monday, November 9, 2026
Neurocrine Biosciences Q3 Earnings Call Highlights
Nov 3, 2026. NBIB-’223, a Friedreich’s ataxia gene therapy being developed with Voyager Therapeutics, is expected to enter phase I in the coming months, with initial patient-level data anticipated in 2027.
Neurocrine Biosciences Q3 Earnings Call Highlights
‹
›
Home
View web version